Xalkori
Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer
July 27, 2018Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma
Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori
June 28, 2018Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma
UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Pfizer nabs EU approval for Xalkori for certain lung cancers
August 31, 2016Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer
The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
Two oncology successes for Pfizer
April 22, 2015Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology
Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …
Merck and Pfizer to co-promote cancer drug
April 9, 2015Research and Development, Sales and Marketing Cancer, Merck, Merck KGaA, NSCLC, Pfizer, Xalkori, non-small cell lung cancer, oncology
Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that …
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
Pfizer’s Xalkori impresses in new setting
March 26, 2014Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer
Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …
Cancer drugs lift Pfizer in third quarter
October 30, 2013Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori
Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …
NICE: final ‘no’ for Xalkori
September 25, 2013Sales and Marketing NICE, NSCLC, Pfizer, Xalkori
Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …
Price cut not enough for Pfizer’s Xalkori
August 16, 2013Sales and Marketing NICE, Pfizer, Xalkori, lung cancer
In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
